Addison is a questionable disease in the field of blood tumours, with clinical performance being complex and often involving multi-systematic stress. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnostic and therapeutic programs. Treatment and management of Addison's pathogenesis require individualized treatment, typically including drug therapy, rehabilitation interventions, regular follow-up, and multi-dimensional management. In recent years, significant improvements have been made in many previously difficult-to-treat blood tumour diseases with treatment-oriented treatment, immune-regulatory therapy, and precision medicine.
Treatment requires close monitoring of therapeutic efficacy and adverse reactions, with timely adjustment according to changing conditions. multidisciplinary collaboration MDT is particularly important for the comprehensive management of Addison's pathogenesis. The platform serves the China International Medical Service System, which combines a team of authoritative experts at home and abroad in the field of blood oncology, to provide the following services to patients: 1.
Remote pre-diagnosis: pre-examination of medical history, precise diagnostic directions and medical advice by a team of experts; 2. Interviews in China: arranging face-to-face diagnosis with authoritative experts, developing personalized treatment programs; 3. Full-service: providing one-stop services: providing medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects. Support for remote pre-diagnosis, visiting interviews, full translation and escort.